This website uses cookies to ensure you get the best experience on our website.
Privacy Policy
I Agree
UroToday
Contact
Login
Sign Up Free
Transformative Evidence
mCRPC
PEACE-3 Trial
PROfound Trial
The RALU Study: Treatment Considerations in the First Line Setting of mCRPC
VISION Trial
mHSPC
ARANOTE Trial
ARASENS Trial
nmCRPC
ARAMIS Trial
nmCSPC
EMBARK Trial
PSMA PET Imaging
COBRA Trial
CONDOR Trial
OSPREY Trial
Bladder Cancer
ANKTIVA
Bladder Cancer Detection
CORE-001 Study
ADSTILADRIN
Centers of Excellence
Urologic Oncology
Left Group
Health Policy
Health Policy
Ruchika Talwar, MD
Bladder Cancer
Bladder Cancer
Ashish Kamat, MD
Advanced Bladder Cancer
Shilpa Gupta, MD
Trimodality Therapy
Leslie Ballas, MD
Kidney Cancer
Advanced Kidney Cancer
Pedro Barata, MD, MSc
Endourology
Endourology
Jaime Landman, MD
Prostate Cancer
Localized Prostate Cancer
Matthew R. Cooperberg, MD, MPH
Decipher Genomic Classifier
Imaging Center
Phillip Koo, MD
mHSPC
Neeraj Agarwal, FASCO, MD
nmCRPC
Zachary Klaassen, MD, MSc
mCRPC Treatment
A. Oliver Sartor, MD
PSMA-Targeted Therapy
Advanced Prostate Cancer
Zachary Klaassen, MD, MSc
Disparities: Social Determinants of Health
Disparities: Social Determinants of Health
Samuel L. Washington III, MD, MAS
Translational Prostate Cancer
Translational Science in Prostate Cancer
Andrea Miyahira, Ph.D
Women in Science
Andrea Miyahira, Ph.D
Upper Tract Urothelial Carcinoma
Upper Tract Urothelial Carcinoma
Sam S. Chang, MD, MBA
TESTICULAR, PENILE & RARE GU MALIGNANCIES
Testicular Cancer
Pelvic Health & Reconstruction
Bladder Health
Diane K. Newman, DNP, ANP-BC, FAAN
Pelvic Health
Diane K. Newman, DNP, ANP-BC, FAAN
Society of Urodynamics, Female Pelvic Medicine & Urogenital Reconstruction (SUFU)
Stephen R. Kraus, MD
Urologic Catheters (Includes CAUTI)
Diane K. Newman, DNP, ANP-BC, FAAN
Videos
Exclusives
Conferences
Exclusive Collaborations
Independent Medical Education
Covid-19
The Prostate Cancer Foundation
Health Policy in Urological Diseases
Disparities: Social Determinants of Health
Practice Guidelines Reviews
Urologic Oncology
Prostate Cancer
Bladder Cancer
Kidney Cancer
Upper Tract Urothelial Tumors
Testicular Cancer
Endourology
Pelvic Health & Reconstruction
Pelvic Health & Reconstruction
Trials in Progress
Trials in Progress
Bladder Cancer
IMMORTAL
PIVOT-006
Kidney Cancer
RadiCal
SAMURAI
Middle Side
Prostate Cancer
ARAMON
ARASEC
ARASTEP
CLARIFY
ECLIPSE
ESCAPE
FORT
Right Side
Prostate Cancer
Masofaniten (EPI-7386)
METANOVA
NRG-GU 0101
PROMISE
RTIRE
SECuRE
SHORTER
Clinical Trials
From the Editor
Search Clinical Trials
Articles
Urology (benign and malignant)
Urologic Oncology
Men's Health
Endourology & Stones
Pediatric Urology
COVID-19 and Genitourinary Cancers
Pelvic Health
Pelvic Health & Reconstruction
Conference Coverage
Recent Conferences
SCS AUA 2024
ASTRO 2024
IBCN 2024
ESMO 2024
BCAN TT 2024
All Conferences
View All
Quick Takes
ESMO 2024
PCF
UroToday Home
Conference Highlights
ESMO 2023
ESMO 2023
Prostate Cancer
Bladder Cancer
Kidney Cancer
Testicular and Penile Cancer
Press Releases
ESMO 2023 Kidney Cancer
Viewing 1-20 of 20 articles
ESMO 2023: State-of-the-Art in Adjuvant Treatment of Renal Cell Carcinoma
ESMO 2023: Comparative Effectiveness of Second Line Treatment with Cabozantinib in Patients with Metastatic Clear Cell RCC after First Line Treatment with Ipilimumab + Nivolumab vs. PD-1/L1 inhibitor + TKI
ESMO 2023: Advances in the Molecular Understanding of GU Cancers: The Next Generation of Therapeutic Targets
ESMO 2023: Prediction of Toxicity in Current Systemic Treatment of Genitourinary Cancers
ESMO 2023: CLEAR Trial, Post Hoc Analysis of the Tumor Response by Baseline Metastases in Patients with Renal Cell Carcinoma Treated with Lenvatinib + Pembrolizumab vs Sunitinib
ESMO 2023: Discussant - MEDI5752 (Volrustomig) for 1st Line Advanced Clear Cell Renal Cell Carcinoma & TIDE-A
ESMO 2023: TIDE-A: Phase II Study of Avelumab plus Intermittent Axitinib in Previously Untreated Patients with mRCC
ESMO 2023: MEDI5752 (Volrustomig), a Novel PD-1/CTLA-4 Bispecific Antibody, in the First-Line Treatment of 65 Patients with Advanced Clear Cell Renal Cell Carcinoma
ESMO 2023: Adjuvant Everolimus in Patients with Completely Resected Very High-Risk RCC and Clear Cell Histology: Results from the Phase III SWOG S0931 (EVEREST) Trial
ESMO 2023: A Pooled Meta-Analysis of Salvage Nivolumab/Ipilimumab after Nivolumab in Patients with Advanced Renal Cell Carcinoma
ESMO 2023: Invited Discussant – RENOTORCH: Toripalimab Combined with Axitinib versus Sunitinib in First-line Treatment of Advanced Renal-Cell Carcinoma: A randomized, Open-label, Phase 3 Study
ESMO 2023: Invited Discussant for LITESPARK-003, LITESPARK-005, and LITESPARK-013
ESMO 2023: RENOTORCH: Toripalimab Combined with Axitinib versus Sunitinib in First-line Treatment of Advanced Renal-Cell Carcinoma: A randomized, Open-label, Phase 3 Study
ESMO 2023: LITESPARK-013 Phase 2- Safety and Efficacy of Two Doses of Belzutifan in Patients with Advanced Renal Cell Carcinoma (RCC)
ESMO 2023: LITESPARK-005 Belzutifan Versus Everolimus in Participants with Previously Treated Advanced Clear Cell Renal Cell Carcinoma: Randomized Open-Label Phase 3
ESMO 2023: STELLAR-304: A Randomized Phase 3 Study of Zanzalintinib (XL092) and Nivolumab in Non-Clear Cell Renal Cell Carcinoma
ESMO 2023: LITESPARK-003 Phase 2 Study of Belzutifan in Combination With Cabozantinib for Advanced Clear Cell Renal Cell Carcinoma (ccRCC)
ESMO 2023: New Therapeutic Targets in Advanced Renal Cell Carcinoma (RCC) and Data from Sequencing Trials
ESMO 2023: What is the Role of Localized Therapies in Metastatic Renal Cell Carcinoma (RCC)?
ESMO 2023: Evolving Frontline Treatment Paradigms in Advanced Renal Cell Carcinoma
×
Login
Login to update email address, newsletter preferences and use bookmarks.
Email
Password
Login
Forgot Password?
Sign Up Free